SCHEMBL2124911

SCHEMBL2124911

Cc1nc2ccccc2c(-n2ccc3ccccc32)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 1/20 0.44
▸ GPR3 P46089 1/20 0.43
▸ PDE10A Q9Y233 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ POLB P06746 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ PTPN2 P17706 1/20 0.41
▸ PTPN1 P18031 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ CDC7 O00311 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ ROCK1 Q13464 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ NUDT1 P36639 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14259395 0.84 TERT (0.47) TERTMAPTHSD17B10KDM4ELMNA
SCHEMBL13483670 0.76 BIRC5 (0.50) MAPTALDH1A1CDC7CDK2ROCK1
SCHEMBL27616510 0.70 CYP1A2 (0.56) GPR3PDE10AHSD17B10KDM4EPOLB
SCHEMBL231530 0.68 GPR3 (0.64) GPR3PDE10AMAPTHSD17B10KDM4E
SCHEMBL19206978 0.67 SMN1; SMN2 (0.53) TERTMAPTKDM4ELMNAALDH1A1
Ammonia Solution, Strong SCHEMBL28822932 0.67 GPR3 (0.61) GPR3PDE10AMAPTHSD17B10KDM4E
Hydrochloric Acid SCHEMBL27521191 0.67 GPR3 (0.61) GPR3PDE10AMAPTHSD17B10KDM4E
SCHEMBL5715598 0.67 BIRC5 (0.41) MAPTALDH1A1CDC7CDK2ROCK1
SCHEMBL22648975 0.67 ALDH1A1 (0.56) TERTMAPTHSD17B10KDM4ELMNA
SCHEMBL6001202 0.67 ACP1 (0.54) MAPTHSD17B10KDM4ELMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 — — US disclosed
EP-2445902-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY Amgen, Inc (US) 2012-05-02 — — EP disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 — — US disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 TERT 1731/4885GPR3 1204/4885PDE10A 3392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback